Field & Main Bank Sells 4,512 Shares of Pfizer Inc. (NYSE:PFE)

Field & Main Bank decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 40.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,565 shares of the biopharmaceutical company’s stock after selling 4,512 shares during the quarter. Field & Main Bank’s holdings in Pfizer were worth $189,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. MCF Advisors LLC raised its stake in shares of Pfizer by 3.7% during the 3rd quarter. MCF Advisors LLC now owns 27,590 shares of the biopharmaceutical company’s stock worth $915,000 after purchasing an additional 975 shares in the last quarter. U.S. Capital Wealth Advisors LLC lifted its stake in Pfizer by 18.5% in the third quarter. U.S. Capital Wealth Advisors LLC now owns 503,170 shares of the biopharmaceutical company’s stock valued at $16,690,000 after acquiring an additional 78,421 shares during the last quarter. Trust Co. of Toledo NA OH grew its position in shares of Pfizer by 2.1% in the 3rd quarter. Trust Co. of Toledo NA OH now owns 122,829 shares of the biopharmaceutical company’s stock valued at $4,074,000 after acquiring an additional 2,567 shares during the period. JGP Wealth Management LLC increased its stake in shares of Pfizer by 3.4% during the 3rd quarter. JGP Wealth Management LLC now owns 60,487 shares of the biopharmaceutical company’s stock worth $2,006,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Blossom Wealth Management raised its holdings in shares of Pfizer by 11.5% in the 3rd quarter. Blossom Wealth Management now owns 10,943 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 1,130 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Finally, Guggenheim began coverage on shares of Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, Pfizer has a consensus rating of “Hold” and an average price target of $36.33.

Pfizer Price Performance

NYSE:PFE traded up $0.25 during trading hours on Monday, reaching $25.65. 41,630,566 shares of the company were exchanged, compared to its average volume of 41,999,020. The company has a market capitalization of $145.24 billion, a P/E ratio of 71.25, a P/E/G ratio of 1.14 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The business has a 50 day moving average of $26.92 and a 200 day moving average of $28.31. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $40.37.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. Pfizer’s revenue was down 41.3% on a year-over-year basis. During the same quarter last year, the business earned $1.14 earnings per share. Research analysts forecast that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.55%. Pfizer’s dividend payout ratio (DPR) is 466.67%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.